Investment Thesis

Viatris Inc. (VTRS) is a BUY at current prices, trading at $16.48. The market is underestimating the company's potential for long-term growth driven by its diverse portfolio of generic and specialty drugs, robust biosimilars offerings, and expansion into emerging markets. Viatris has the fundamentals to capitalize on the rising global demand for affordable healthcare solutions, particularly in regions where access to pharmaceuticals is increasing, positioning the company for significant upside as it leverages its established market presence.

Competitive Moat

characterized by scale economies and intangible assets, particularly its extensive portfolio of established brands and regulatory approvals. The company benefits from its ability to produce a wide range of generic and specialty medications, which creates a significant barrier to entry for new competitors. However, threats from emerging generic manufacturers and price competition from biosimilars pose challenges to maintaining this advantage. Over the next 5-10 years, Viatris’ moat is likely to remain intact, but vigilance regarding competitive pressures is necessary.

Growth Engine

Future revenue growth for Viatris will primarily stem from its extensive pipeline of biosimilars and generics, as well as geographic expansion into high-growth markets. The total addressable market (TAM) for biosimilars alone is projected to grow significantly as healthcare systems worldwide shift towards cost-effective treatment options. Viatris is gaining market share in several therapeutic areas, driven by its commitment to innovation and strategic partnerships, such as those with Revance Therapeutics and Biocon. This organic growth strategy, coupled with selective acquisitions, positions the company favorably for sustainable revenue increases.